Regulation of Microtubule, Apoptosis, and Cell Cycle-related Genes by Taxotere in Prostate Cancer Cells Analyzed by Microarray

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2004 May 14

PMID 15140405

Citations 19

Authors

Yiwei Li

Xingli Li

Maha Hussain

Fazlul H Sarkar

Affiliations

Soon will be listed here.

Abstract

Taxotere showed antitumor activity against solid tumors including prostate cancer. However, the molecular mechanism(s) of action of Taxotere has not been fully elucidated. In order to establish such molecular mechanism(s) in both hormone-insensitive (PC3) and hormone-sensitive (LNCaP) prostate cancer cells, comprehensive gene expression profiles were obtained by Affymetrix Human Genome U133A Array. The RNA from the cells treated with 2 nM Taxotere was subjected to microarray analysis. We found that a total of 166, 365, and 1785 genes showed greater than two-fold change in PC3 cells after 6, 36, and 72 hours of treatment, respectively compared to 57, 823, and 964 genes in LNCaP cells. The expression of tubulin was decreased, whereas the expression of microtubule-associated proteins was increased in Taxotere-treated prostate cancer cells, confirming the microtubule-targeting effect of Taxotere. Clustering analysis showed downregulation of some genes for cell proliferation and cell cycle. In contrast, Taxotere upregulated some genes that are related to induction of apoptosis and cell cycle arrest. From these results, we conclude that Taxotere caused alterations of a large number of genes, many of which may contribute to the molecular mechanism(s) by which Taxotere affects prostate cancer cells. Further molecular studies are needed in order to determine the cause and effect relationships between these genes altered by Taxotere. Nevertheless, our results could be further exploited for devising strategies to optimize therapeutic effects of Taxotere for the treatment of prostate cancer.

Citing Articles

Synergistic enhancement of cell death by triple combination therapy of docetaxel, ultrasound and microbubbles, and radiotherapy on PC3 a prostate cancer cell line.

Almasri F, Karshafian R Heliyon. 2022; 8(8):e10213.

PMID: 36033334 PMC: 9404355. DOI: 10.1016/j.heliyon.2022.e10213.

Cellular uptake and cytotoxicity studies of pH-responsive polymeric nanoparticles fabricated by dispersion polymerization.

Puri R, Adesina S, Akala E J Nanosci Nanomed. 2021; 2(1):3-18.

PMID: 34263267 PMC: 8276970.

Synergistic Anticancer Effect of Paclitaxel and Noscapine on Human Prostate Cancer Cell Lines.

Rabzia A, Khazaei M, Rashidi Z, Khazaei M Iran J Pharm Res. 2018; 16(4):1432-1442.

PMID: 29552052 PMC: 5843305.

CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes.

Jung Y, Cackowski F, Yumoto K, Decker A, Wang J, Kim J Cancer Res. 2018; 78(8):2026-2039.

PMID: 29431639 PMC: 6324566. DOI: 10.1158/0008-5472.CAN-17-2332.

Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells.

Levrier C, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis R Cell Cycle. 2017; 17(5):652-668.

PMID: 28749250 PMC: 5976206. DOI: 10.1080/15384101.2017.1356512.

References

El-Deiry W, Tokino T, Waldman T, Oliner J, Velculescu V, Burrell M . Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 1995; 55(13):2910-9. View

Miyoshi Y, Iwao K, Egawa C, Noguchi S . Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer. 2001; 92(3):370-3. DOI: 10.1002/ijc.1200. View

Fulton B, Spencer C . Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs. 1996; 51(6):1075-92. DOI: 10.2165/00003495-199651060-00011. View

Haldar S, Basu A, Croce C . Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997; 57(2):229-33. View

Downing K, Nogales E . Tubulin and microtubule structure. Curr Opin Cell Biol. 1998; 10(1):16-22. DOI: 10.1016/s0955-0674(98)80082-3. View

Avramis V, Nandy P, Kwock R, Solorzano M, Mukherjee S, Danenberg P . Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Anticancer Res. 1998; 18(4A):2327-38. View

Allaman J, Radlgruber G, Meda P, Kiss J, French L, Masson D . The distribution of murine 115-kDa epithelial microtubule-associated protein (E-MAP-115) during embryogenesis and in adult organs suggests a role in epithelial polarization and differentiation. Differentiation. 1998; 63(4):169-80. DOI: 10.1111/j.1432-0436.1998.00169.x. View

Eisen M, Spellman P, Brown P, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95(25):14863-8. PMC: 24541. DOI: 10.1073/pnas.95.25.14863. View

Still I, Vince P, Cowell J . The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics. 1999; 58(2):165-70. DOI: 10.1006/geno.1999.5829. View

10.

Stein C . Mechanisms of action of taxanes in prostate cancer. Semin Oncol. 1999; 26(5 Suppl 17):3-7. View

11.

Friedland D, Cohen J, MILLER Jr R, Voloshin M, Gluckman R, Lembersky B . A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol. 1999; 26(5 Suppl 17):19-23. View

12.

Oh W, Kantoff P . Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. Semin Oncol. 1999; 26(5 Suppl 17):49-54. View

13.

Nilsson I, Hoffmann I . Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res. 2000; 4:107-14. DOI: 10.1007/978-1-4615-4253-7_10. View

14.

Erlanson M, Landberg G . Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas. Leuk Lymphoma. 2001; 40(5-6):461-70. DOI: 10.3109/10428190109097645. View

15.

Poggioli G, Dermody T, Tyler K . Reovirus-induced sigma1s-dependent G(2)/M phase cell cycle arrest is associated with inhibition of p34(cdc2). J Virol. 2001; 75(16):7429-34. PMC: 114978. DOI: 10.1128/JVI.75.16.7429-7434.2001. View

16.

Luo Y, Kroeger P, Frost L, Chen Z, Han E, Ng S . Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism. Neoplasia. 2001; 3(5):411-9. PMC: 1506209. DOI: 10.1038/sj.neo.7900175. View

17.

Gopalkrishnan R, Kang D, Fisher P . Molecular markers and determinants of prostate cancer metastasis. J Cell Physiol. 2001; 189(3):245-56. DOI: 10.1002/jcp.10023. View

18.

Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y . Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 2002; 62(2):518-27. View

19.

Khatri P, Draghici S, Ostermeier G, Krawetz S . Profiling gene expression using onto-express. Genomics. 2002; 79(2):266-70. DOI: 10.1006/geno.2002.6698. View

20.

Obaya A, Sedivy J . Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci. 2002; 59(1):126-42. PMC: 11337483. DOI: 10.1007/s00018-002-8410-1. View